Indomethacin for post-endoscopic retrograde cholangiopancreatography pancreatitis prophylaxis:Is it the magic bullet?  

作　　者：Dennis Yang Peter V Draganov 

机构地区：[1]Division of Gastroenterology,Hepatology and Nutrition,Department of Medicine,University of Florida,Gainesville,FL 32610,United States

出　　处：《World Journal of Gastroenterology》2012年第31期4082-4085,共4页世界胃肠病学杂志（英文版）

摘　　要：Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography(ERCP).Pancreatic duct stent insertion after ERCP has been widely accepted as the standard of care for the prevention of this complication in high-risk patients.Unfortunately,the placement of pancreatic stents requires higher level of endoscopic expertise and is not always feasible due to anatomic considerations.Therefore,effective non-invasive pharmacologic prophylaxis remains appealing,particularly if it is inexpensive,easily administered,has a low risk side effect profile and is widely available.There have been multiple studies evaluating potential pharmacologic candidates for post-ERCP pancreatitis(PEP) prophylaxis,most of them yielding disappointing results.A recently published large,multicenter,randomized controlled trial reported that in high risk patients a single dose of rectal indomethacin administered immediately after the ERCP significantly decreased the incidence of PEP compare to placebo.Acute pancreatitis is a common complication of endo- scopic retrograde cholangiopancreatography （ERCP）. Pancreatic duct stent insertion after ERCP has been widely accepted as the standard of care for the preven- tion of this complication in high-risk patients. Unfortunately, the placement of pancreatic stents requires higher level of endoscopic expertise and is not always feasible due to anatomic considerations. Therefore, ef- fective non-invasive pharmacologic prophylaxis remains appealing, particularly if it is inexpensive, easily admin- istered, has a low risk side effect profile and is widely available. There have been multiple studies evaluat- ing potential pharmacologic candidates for post-ERCP pancreatitis （PEP） prophylaxis, most of them yielding disappointing results. A recently published large, multicenter, randomized controlled trial reported that in high risk patients a single dose of rectal indomethacin administered immediately after the ERCP significantly decreased the incidence of PEP compare to placebo.

关 键 词：Non-steroidal anti-inflammatory drugs In-domethacin Post-endoscopic retrograde cholangiopan-creatography pancreatitis Acute pancreatitis 

分 类 号：R576[医药卫生—消化系统]